Annual FCF
-$135.49 M
+$39.34 M+22.50%
31 December 2023
Summary:
Esperion Therapeutics annual free cash flow is currently -$135.49 million, with the most recent change of +$39.34 million (+22.50%) on 31 December 2023. During the last 3 years, it has fallen by -$36.94 million (-37.49%). ESPR annual FCF is now -1388.48% below its all-time high of -$9.10 million, reached on 31 December 2011.ESPR Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$35.49 M
-$28.21 M-387.39%
30 September 2024
Summary:
Esperion Therapeutics quarterly free cash flow is currently -$35.49 million, with the most recent change of -$28.21 million (-387.39%) on 30 September 2024. Over the past year, it has dropped by -$16.17 million (-83.66%). ESPR quarterly FCF is now -125.57% below its all-time high of $138.81 million, reached on 30 June 2020.ESPR Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$26.07 M
-$16.17 M-163.17%
30 September 2024
Summary:
Esperion Therapeutics TTM free cash flow is currently -$26.07 million, with the most recent change of -$16.17 million (-163.17%) on 30 September 2024. Over the past year, it has increased by +$114.83 million (+81.49%). ESPR TTM FCF is now -867.10% below its all-time high of -$2.70 million, reached on 31 March 2012.ESPR TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ESPR Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +22.5% | -83.7% | +81.5% |
| 3 y3 years | -37.5% | +48.7% | +90.9% |
| 5 y5 years | +8.9% | +39.2% | +47.8% |
ESPR Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -37.5% | +48.6% | -166.0% | +48.7% | -163.2% | +90.9% |
| 5 y | 5 years | -90.0% | +48.6% | -125.6% | +60.1% | -163.2% | +91.4% |
| alltime | all time | -1388.5% | +48.6% | -125.6% | +60.1% | -867.1% | +91.4% |
Esperion Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$35.49 M(+387.4%) | -$26.07 M(+163.2%) |
| June 2024 | - | -$7.28 M(-113.5%) | -$9.91 M(-63.8%) |
| Mar 2024 | - | $53.76 M(-245.1%) | -$27.38 M(-79.8%) |
| Dec 2023 | -$135.49 M(-22.5%) | -$37.06 M(+91.8%) | -$135.49 M(-3.8%) |
| Sept 2023 | - | -$19.32 M(-21.9%) | -$140.90 M(-14.3%) |
| June 2023 | - | -$24.75 M(-54.5%) | -$164.41 M(-13.6%) |
| Mar 2023 | - | -$54.36 M(+28.0%) | -$190.19 M(+8.8%) |
| Dec 2022 | -$174.83 M(-33.7%) | -$42.47 M(-0.8%) | -$174.83 M(-8.0%) |
| Sept 2022 | - | -$42.83 M(-15.2%) | -$190.06 M(-12.2%) |
| June 2022 | - | -$50.53 M(+29.6%) | -$216.40 M(+1.2%) |
| Mar 2022 | - | -$38.99 M(-32.4%) | -$213.73 M(-19.0%) |
| Dec 2021 | -$263.81 M(+167.7%) | -$57.71 M(-16.6%) | -$263.81 M(-8.2%) |
| Sept 2021 | - | -$69.17 M(+44.5%) | -$287.33 M(-5.7%) |
| June 2021 | - | -$47.87 M(-46.3%) | -$304.75 M(+158.1%) |
| Mar 2021 | - | -$89.07 M(+9.7%) | -$118.08 M(+19.8%) |
| Dec 2020 | -$98.55 M(+38.2%) | -$81.23 M(-6.2%) | -$98.55 M(+46.0%) |
| Sept 2020 | - | -$86.59 M(-162.4%) | -$67.49 M(+71.8%) |
| June 2020 | - | $138.81 M(-299.6%) | -$39.28 M(-83.1%) |
| Mar 2020 | - | -$69.54 M(+38.6%) | -$232.33 M(+225.9%) |
| Dec 2019 | -$71.29 M(-52.1%) | -$50.17 M(-14.1%) | -$71.29 M(+42.8%) |
| Sept 2019 | - | -$58.39 M(+7.6%) | -$49.92 M(+71.5%) |
| June 2019 | - | -$54.24 M(-159.3%) | -$29.11 M(+107.0%) |
| Mar 2019 | - | $91.50 M(-417.7%) | -$14.07 M(-90.5%) |
| Dec 2018 | -$148.79 M(+13.3%) | -$28.80 M(-23.4%) | -$148.79 M(-3.9%) |
| Sept 2018 | - | -$37.57 M(-4.1%) | -$154.87 M(+1.1%) |
| June 2018 | - | -$39.20 M(-9.3%) | -$153.18 M(+9.2%) |
| Mar 2018 | - | -$43.22 M(+23.9%) | -$140.21 M(+6.8%) |
| Dec 2017 | -$131.32 M | -$34.87 M(-2.8%) | -$131.32 M(+16.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2017 | - | -$35.88 M(+36.8%) | -$112.85 M(+23.6%) |
| June 2017 | - | -$26.23 M(-23.6%) | -$91.27 M(+26.2%) |
| Mar 2017 | - | -$34.33 M(+109.3%) | -$72.35 M(+51.3%) |
| Dec 2016 | -$47.82 M(+24.3%) | -$16.41 M(+14.7%) | -$47.82 M(+19.3%) |
| Sept 2016 | - | -$14.30 M(+95.6%) | -$40.10 M(+6.4%) |
| June 2016 | - | -$7.31 M(-25.4%) | -$37.70 M(-3.4%) |
| Mar 2016 | - | -$9.80 M(+13.0%) | -$39.01 M(+1.4%) |
| Dec 2015 | -$38.48 M(+17.0%) | -$8.68 M(-27.1%) | -$38.48 M(+1.2%) |
| Sept 2015 | - | -$11.91 M(+38.0%) | -$38.03 M(+8.7%) |
| June 2015 | - | -$8.63 M(-6.9%) | -$34.97 M(+6.7%) |
| Mar 2015 | - | -$9.27 M(+12.7%) | -$32.79 M(-0.3%) |
| Dec 2014 | -$32.89 M(+81.3%) | -$8.23 M(-7.0%) | -$32.89 M(+2.1%) |
| Sept 2014 | - | -$8.85 M(+37.3%) | -$32.21 M(+14.5%) |
| June 2014 | - | -$6.44 M(-31.3%) | -$28.14 M(+13.0%) |
| Mar 2014 | - | -$9.38 M(+24.3%) | -$24.89 M(+37.2%) |
| Dec 2013 | -$18.14 M(+67.8%) | -$7.54 M(+57.9%) | -$18.14 M(+39.9%) |
| Sept 2013 | - | -$4.78 M(+49.4%) | -$12.97 M(+16.9%) |
| June 2013 | - | -$3.20 M(+21.7%) | -$11.10 M(+3.3%) |
| Mar 2013 | - | -$2.63 M(+11.1%) | -$10.75 M(-0.6%) |
| Dec 2012 | -$10.81 M(+18.8%) | -$2.37 M(-18.6%) | -$10.82 M(+28.0%) |
| Sept 2012 | - | -$2.91 M(+2.1%) | -$8.45 M(+52.4%) |
| June 2012 | - | -$2.85 M(+5.6%) | -$5.54 M(+105.6%) |
| Mar 2012 | - | -$2.70 M | -$2.70 M |
| Dec 2011 | -$9.10 M(-67.2%) | - | - |
| Dec 2002 | -$27.72 M(+11.8%) | - | - |
| Dec 2001 | -$24.79 M(+28.5%) | - | - |
| Dec 2000 | -$19.30 M(+104.9%) | - | - |
| Dec 1999 | -$9.42 M | - | - |
FAQ
- What is Esperion Therapeutics annual free cash flow?
- What is the all time high annual FCF for Esperion Therapeutics?
- What is Esperion Therapeutics annual FCF year-on-year change?
- What is Esperion Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Esperion Therapeutics?
- What is Esperion Therapeutics quarterly FCF year-on-year change?
- What is Esperion Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Esperion Therapeutics?
- What is Esperion Therapeutics TTM FCF year-on-year change?
What is Esperion Therapeutics annual free cash flow?
The current annual FCF of ESPR is -$135.49 M
What is the all time high annual FCF for Esperion Therapeutics?
Esperion Therapeutics all-time high annual free cash flow is -$9.10 M
What is Esperion Therapeutics annual FCF year-on-year change?
Over the past year, ESPR annual free cash flow has changed by +$39.34 M (+22.50%)
What is Esperion Therapeutics quarterly free cash flow?
The current quarterly FCF of ESPR is -$35.49 M
What is the all time high quarterly FCF for Esperion Therapeutics?
Esperion Therapeutics all-time high quarterly free cash flow is $138.81 M
What is Esperion Therapeutics quarterly FCF year-on-year change?
Over the past year, ESPR quarterly free cash flow has changed by -$16.17 M (-83.66%)
What is Esperion Therapeutics TTM free cash flow?
The current TTM FCF of ESPR is -$26.07 M
What is the all time high TTM FCF for Esperion Therapeutics?
Esperion Therapeutics all-time high TTM free cash flow is -$2.70 M
What is Esperion Therapeutics TTM FCF year-on-year change?
Over the past year, ESPR TTM free cash flow has changed by +$114.83 M (+81.49%)